Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
AbbVie cut its Q3 adjusted diluted EPS guidance to USD 3.73-3.77 from USD 3.84-3.88, citing acquired IPR&D and milestones expense of USD 216 million, equal to a USD 0.11 per-share hit. Full-year guidance was also lowered.
Consensus $14.25. AbbVie's full-year 2026 adjusted diluted earnings per share guidance range, including the impact of second-quarter 2026 acquired IPR&D and milestones expense, is $13.91 - $14.11. AbbVie's second-quarter 2026 adjusted diluted earnings per share guidance range, including the impact of second-quarter 202
Abbvie sees Apogee deal hurting 2026 adjusted EPS by 14c/shr and 2027 adjusted EPS by 46c/shr